Generic Name and Formulations:
Tolterodine tartrate 2mg, 4mg; ext-rel caps.
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
Swallow whole. 4mg once daily; may decrease to 2mg once daily. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir), or severe renal or mild to moderate hepatic dysfunction: 2mg once daily. Severe hepatic impairment, CrCl<10mL/min: not recommended.
Urinary or gastric retention. Uncontrolled narrow-angle glaucoma. Fesoterodine fumarate allergy.
Bladder outflow obstruction. GI obstruction (eg, pyloric stenosis). Decreased GI motility. Discontinue if angioedema occurs. Monitor for anticholinergic CNS effects (esp. when starting treatment and after dose increases). Narrow-angle glaucoma. Myasthenia gravis. History of QT prolongation. Pregnancy (Cat.C). Nursing mothers: not recommended.
Plasma levels increased by CYP3A4 inhibitors (see Adult dose). Caution with Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics. Additive anticholinergic effects with other anticholinergics.
Dry mouth/eyes, dyspepsia, fatigue, dizziness, somnolence, sinusitis, abnormal vision, anxiety, dysuria, other anticholinergic effects, anaphylaxis, angioedema.
Hepatic (CYP2D6, 3A4).
Renal (primarily), fecal.
LA—30, 90, 500; Tabs—60, 500
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...